{"schema_version":"secwatch.filing_event.v1","accession":"0001649094-25-000027","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.303952+00:00","generated_at":"2026-05-26T04:47:49.037030+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vaxcyte reports Q4 2024 net loss of $137.1M; cash $3.13B; VAX-31 Phase 3 on track for mid-2025","bullets":["Net loss Q4 2024: $137.1M; full year 2024: $463.9M vs $402.3M in 2023.","Cash, cash equivalents and investments: $3.13B at Dec 31, 2024, up from $1.24B a year ago.","R&D expenses $133.6M in Q4; $476.6M for full year on increased PCV program activities.","VAX-31 adult Phase 3 pivotal study expected to start by mid-2025 with topline data in 2026.","VAX-24 infant Phase 2 primary immunization topline data expected by end of Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001649094-25-000027","json":"https://secwatch.observer/filing/0001649094-25-000027.json","markdown":"https://secwatch.observer/filing/0001649094-25-000027.md","text":"https://secwatch.observer/filing/0001649094-25-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000164909425000027/0001649094-25-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000164909425000027/pcvx-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:47:49.037030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}